CINECA IRIS Institutional Research Information System

SALANI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.554
AS - Asia 2.130
EU - Europa 1.185
SA - Sud America 287
AF - Africa 129
OC - Oceania 5
Totale 6.290
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.471
SG - Singapore 809
CN - Cina 551
IT - Italia 460
HK - Hong Kong 246
BR - Brasile 224
VN - Vietnam 181
SE - Svezia 146
DE - Germania 106
GB - Regno Unito 93
FR - Francia 57
IN - India 56
CI - Costa d'Avorio 54
JP - Giappone 52
FI - Finlandia 49
KR - Corea 49
AT - Austria 46
NL - Olanda 46
RU - Federazione Russa 44
BG - Bulgaria 39
CA - Canada 31
BD - Bangladesh 30
AR - Argentina 27
IQ - Iraq 26
MX - Messico 25
PL - Polonia 22
TR - Turchia 20
NG - Nigeria 19
PK - Pakistan 14
ES - Italia 12
ID - Indonesia 12
SN - Senegal 12
UA - Ucraina 12
VE - Venezuela 12
LT - Lituania 11
ZA - Sudafrica 11
CH - Svizzera 9
KE - Kenya 9
UZ - Uzbekistan 9
JO - Giordania 8
MY - Malesia 8
SA - Arabia Saudita 8
EC - Ecuador 7
BE - Belgio 6
CR - Costa Rica 6
CZ - Repubblica Ceca 6
LB - Libano 6
RO - Romania 6
CO - Colombia 5
EG - Egitto 5
IR - Iran 5
MA - Marocco 5
PH - Filippine 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
NP - Nepal 4
PS - Palestinian Territory 4
AL - Albania 3
IE - Irlanda 3
KZ - Kazakistan 3
OM - Oman 3
PE - Perù 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
TW - Taiwan 3
AO - Angola 2
AZ - Azerbaigian 2
BO - Bolivia 2
CL - Cile 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
GD - Grenada 2
HN - Honduras 2
JM - Giamaica 2
NI - Nicaragua 2
PA - Panama 2
PY - Paraguay 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
DM - Dominica 1
EE - Estonia 1
GH - Ghana 1
GT - Guatemala 1
GY - Guiana 1
HU - Ungheria 1
IL - Israele 1
IS - Islanda 1
KH - Cambogia 1
LK - Sri Lanka 1
LV - Lettonia 1
MD - Moldavia 1
MM - Myanmar 1
NO - Norvegia 1
Totale 6.283
Salva come PNG Salva come JPEG
Città #
Singapore 465
Ashburn 364
San Jose 349
Hong Kong 240
Dallas 220
Santa Clara 201
Shanghai 117
Chandler 90
Los Angeles 86
Council Bluffs 84
New York 81
Hefei 80
Milan 76
Beijing 66
Boardman 59
Fairfield 55
Abidjan 54
Munich 52
Seoul 48
Ho Chi Minh City 46
Tokyo 45
Florence 43
London 39
Sofia 39
Hanoi 38
Seattle 34
Vienna 32
Buffalo 28
Pisa 25
Lauterbourg 24
Colorado Springs 23
Turku 22
Frankfurt am Main 20
Woodbridge 20
Lagos 19
Lawrence 18
Princeton 18
Warsaw 18
Cambridge 17
Wilmington 17
Helsinki 16
Houston 16
Redondo Beach 16
Orem 15
Baghdad 14
Hyderabad 14
Rome 14
Istanbul 13
Kent 13
Memphis 13
Nuremberg 13
São Paulo 13
Da Nang 12
Dakar 12
Montreal 12
Ogden 12
Medford 11
Baltimore 10
Boston 10
Brooklyn 10
Chennai 10
Chicago 10
Düsseldorf 10
Lappeenranta 10
Mexico City 10
Quanzhou 10
Denver 9
San Diego 9
Tashkent 9
Amman 8
Cascina 8
Curitiba 8
Haiphong 8
Portsmouth 8
Stockholm 8
Ann Arbor 7
Fuzhou 7
Guangzhou 7
Nairobi 7
Poplar 7
Salt Lake City 7
The Dalles 7
Amsterdam 6
Dhaka 6
Jeddah 6
Karachi 6
Phoenix 6
Rio de Janeiro 6
Zurich 6
Atlanta 5
Goiânia 5
Hải Dương 5
Naples 5
Newark 5
Norwalk 5
Salvador 5
San Francisco 5
Thái Nguyên 5
Toronto 5
Turin 5
Totale 3.912
Salva come PNG Salva come JPEG
Nome #
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer 187
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study 174
Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle 172
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 161
Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies 160
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 159
Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist? 152
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 151
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 141
Correction to: Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies 141
Role of Baseline Computed-Tomography-Evaluated Body Composition in Predicting Outcome and Toxicity from First-Line Therapy in Advanced Gastric Cancer Patients 140
Abdominal Visceral-to-Subcutaneous Fat Volume Ratio Predicts Survival and Response to First-Line Palliative Chemotherapy in Patients with Advanced Gastric Cancer 138
Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients 138
Dynamic profiling of the immune tumor microenvironment in locally advanced gastric cancer treated with perioperative chemotherapy 135
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 134
Invasive Meningococcal Disease due to group C N. meningitidis ST11 (cc11): The Tuscany cluster 2015–2016 133
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study 127
Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib 123
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 123
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 120
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 120
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 119
Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology 118
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 118
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 117
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 115
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 112
Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice 105
Concordance of PD-L1 status in primary gastroesophageal adenocarcinoma and matched peritoneal metastases: a single institution study 101
Network meta-analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence 100
Combination chemotherapy in patients with advanced pancreatic cancer with an eastern cooperative oncology group performance status of 2: Lights and shadows of a frail route 100
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 93
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 93
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 89
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma 87
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 82
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab 82
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer 81
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 81
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction 78
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action 77
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 75
Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Carcinomatosis: The Need for Clear Answers Through Proper Questions 75
In Reply 74
Evolving Landscape in Liver Transplantation for Hepatocellular Carcinoma: From Stage Migration to Immunotherapy Revolution 69
Comprehensive analysis of differentially expressed miRNAs in hepatocellular carcinoma: Prognostic, predictive significance and pathway insights 69
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 67
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy 66
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 63
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 61
null 59
Comprehensive analysis of differentially expressed miRNAs in Hepatocellular carcinoma: prognostic significance and pathway insights 55
Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis 52
null 48
Attenuation-based estimation of myocardial extracellular volume from ECG-ungated whole-body CT examinations as an early biomarker of chemotherapy-induced cardiotoxicity: preliminary findings 45
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib 45
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 42
Viral Hepatitis in Western Patients with Advanced Intrahepatic Cholangiocarcinoma: Retrospective Assessment of Prevalence, Prognostic and Predictive Significance 41
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 41
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 37
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 37
null 34
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 33
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers 33
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 32
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 32
Precision epigenetic therapies in oncology 31
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis 31
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 30
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi‐Center Real‐World Study 26
Attenuation-based estimation of myocardial extracellular volume from ECG-ungated whole-body CT examinations as an early biomarker of chemotherapy-induced cardiotoxicity: preliminary findings 17
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 16
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab 15
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study 14
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis 11
Totale 6.453
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.304
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.304
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202113 0 0 0 0 0 0 0 0 0 0 0 13
2021/2022204 0 1 3 6 42 41 6 2 19 14 22 48
2022/2023465 50 70 34 15 51 59 6 36 94 2 39 9
2023/2024424 21 41 42 26 58 40 65 16 5 17 41 52
2024/20251.999 14 99 46 84 151 310 132 96 172 193 264 438
2025/20263.189 233 314 270 248 348 245 520 216 197 342 186 70
Totale 6.453